Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CAD

National and Kapodistrian University of Athens

Status: Unknown

Conditions: Amyloid; Diabetes; Insulin Resistance; Clopidogrel Resistance

Study type: Observational

Funder types: Other

Identifiers

NCT04027712

LTA_MOTS-c_bamyloid_DM_CAD

Details and patient eligibility

About

Increased circulating b-amyloid and decreased Mitochondrial-derived peptide (MOTS-c), a peptide improving tissue insulin sensitivity, are reported in diabetes. The investigators plan to investigate the association of both biofactors with high on-clopidogrel platelet reactivity and cardiovascular mortality in type 2 diabetic patients with Coronary artery disease

Full description

In type II diabetic patients with Coronary artery disease treated with clopidogrel and aspirin, the investigators plan to measure: i. maximum platelet aggregation to adenosine diphosphate (ADP) by Light Transmission Aggregometry (LTAmax), as a marker of on-clopidogrel treatment platelet reactivity ii. Malondialdehyde (MDA), as oxidative stress marker, Mitochondrial-derived peptide MOTS-c and b-amyloid. blood levels.

Enrollment: 120 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• type 2 diabetic patients with coronary artery disease, documented by coronary angiography,
• both per os or/and parenteral antidiabetic medications and double antiplatelet therapy (DAPT), constituted by a daily dose of 100 mg acetylsalicylic acid per os and a daily dose of 75 mg clopidogrel per os should be prescribed to the patients for at least one month before inclusion in the study

Exclusion criteria

• abnormal renal function (creatinine> 2.5 mg / dl),
• hepatic failure (bilirubin> 2 mg / dl),
• active malignancy,
• patients treated with drugs that affect platelet function, besides aspirin 100 mg qd and clopidogrel 75 mg qd,
• patients with a history of hemorrhagic mood,
• patients with thrombocytopenia (PLTs < 100x109 / L) and
• anemia (HCT <28%).